Search
Famotidine
go.drugbank.com/drugs/DB00927ApprovedInvestigationaldisease, famotidine was about 20 to 50 times more potent at inhibiting gastric acid secretion than [cimetidine] and eight times more potent than [ranitidine] on a weight basis. … [L11166] Compared to other H<sub>2</sub> receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory
Synonyms: N-Sulfamoyl-3-((2-guanidinothiazol-4-yl)methylthio)propionamide, 3-(((2-((Aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)propanimidamideProducts: FAMOTIDINA EG, NEVOFAM-L 20 MG IM/IV LİYOFİLİZE ENJEKTABL TOZ İÇEREN AMPULQuetiapine
go.drugbank.com/drugs/DB01224ApprovedInvestigationalInitially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. … [L8546] Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment.
Products: QUETIAPINA EG, QUETIAPINA EG STADACiprofloxacin
go.drugbank.com/drugs/DB00537ApprovedInvestigational[L6469,L6472,L6475,L6478,L6481,L6484,L6487,L6490,L6493] The first ciprofloxacin containing product was FDA approved on 22 October 1987.[L6463] … Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics.
Products: N/A, ENIAluminum chlorohydrate
go.drugbank.com/drugs/DB11573ApprovedIt is also used as a coagulant in the water purification process. … Aluminum chlorohydrate is a group of water-soluble aluminum complexes with the general formula AlnCl(3n-m)(OH)m.
Mixtures: Watkins Roll On Deodorant, Anti-perspirant Roll-ON DeodProducts: LA FRESH Antiperspirant Wipe, Antiperspirant Deodorant Roll-On Jafra le moireTislelizumab
go.drugbank.com/drugs/DB14922ApprovedInvestigational[A262909] By blocking PD-L1/PD-L2–mediated cell signaling, tislelizumab restores T-cell function through cytokine production, resulting in immune-mediated antitumor responses. … [A262924] On September 25, 2023, tislelizumab gained EMA approval as a monotherapy for adults with esophageal cancer under the brand name TEVIMBRA.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsBeclomethasone dipropionate
go.drugbank.com/drugs/DB00394ApprovedInvestigationalBeclomethasone dipropionate became first available in a pressurized metered-dose inhaler in 1972 and later in a dry powder inhaler and an aqueous nasal spray. … [L6871] It is a prodrug of an active metabolite beclomethasone 17-monopropionate (17-BMP)[A179839] which acts on the glucocorticoid receptor to mediates its therapeutic action.
Mixtures: FORMODUAL N. 200/6UG, FORMODUAL N. 200/6UGInternational brands: Clenil-ALevomenthol
go.drugbank.com/drugs/DB00825ApprovedInvestigationalMenthol is a covalent organic compound made synthetically or obtained from peppermint or other mint oils.
Mixtures: La Jiao Feng Shi Gao, Beech Nut Menthol Cough DropSynonyms: L-menthol, L-(-)-MENTHOLDesipramine
go.drugbank.com/drugs/DB01151ApprovedIn depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. … They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation.
Categories: Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic IndexSynonyms: N-(3-methylaminopropyl)iminobibenzylGedatolisib
go.drugbank.com/drugs/DB11896ApprovedInvestigationalbreast cancer without a PIK3CA mutation detected, following progression on or after at least one line of endocrine therapy in the metastatic setting. … [L63796,L63927] The PI3K/AKT/mTOR pathway is a long-standing target in the breast cancer setting, with previously approved agents acting on a single node of it (i.e. PI3Kα, AKT, or mTORC1).
Amivantamab
go.drugbank.com/drugs/DB16695ApprovedInvestigationalFDA approved the subcutaneous formulation, RYBREVANT FASPRO™, across all existing and expanded indications of amivantamab, including its use as a first-line, chemotherapy-free combination regimen with … [A235133] Amivantamab was granted FDA approval on 21 May 2021,[L34193] followed by the approval by the EMA on 9 December 2021 [L41474] and Health Canada on 30 March 2022.